pharma-wm consultancy limited
pharma-wm consultancy limited Company Information
Company Number
10593192
Next Accounts
Oct 2025
Shareholders
wasim malik
Group Structure
View All
Industry
Other human health activities
Registered Address
unit 4, the office campus, paragon busin, wakefield, WF1 2UY
Website
-pharma-wm consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA-WM CONSULTANCY LIMITED at £11.1k based on a Turnover of £27.7k and 0.4x industry multiple (adjusted for size and gross margin).
pharma-wm consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA-WM CONSULTANCY LIMITED at £0 based on an EBITDA of £-19 and a 3.08x industry multiple (adjusted for size and gross margin).
pharma-wm consultancy limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMA-WM CONSULTANCY LIMITED at £0 based on Net Assets of £-131 and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharma-wm Consultancy Limited Overview
Pharma-wm Consultancy Limited is a live company located in wakefield, WF1 2UY with a Companies House number of 10593192. It operates in the other human health activities sector, SIC Code 86900. Founded in January 2017, it's largest shareholder is wasim malik with a 100% stake. Pharma-wm Consultancy Limited is a young, micro sized company, Pomanda has estimated its turnover at £27.7k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharma-wm Consultancy Limited Health Check
Pomanda's financial health check has awarded Pharma-Wm Consultancy Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 7 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
7 Weak
Size
annual sales of £27.7k, make it smaller than the average company (£642k)
- Pharma-wm Consultancy Limited
£642k - Industry AVG
Growth
3 year (CAGR) sales growth of -21%, show it is growing at a slower rate (7.4%)
- Pharma-wm Consultancy Limited
7.4% - Industry AVG
Production
with a gross margin of 22.6%, this company has a higher cost of product (39%)
- Pharma-wm Consultancy Limited
39% - Industry AVG
Profitability
an operating margin of -0.1% make it less profitable than the average company (5.5%)
- Pharma-wm Consultancy Limited
5.5% - Industry AVG
Employees
with 1 employees, this is below the industry average (16)
1 - Pharma-wm Consultancy Limited
16 - Industry AVG
Pay Structure
on an average salary of £26.2k, the company has an equivalent pay structure (£26.2k)
- Pharma-wm Consultancy Limited
£26.2k - Industry AVG
Efficiency
resulting in sales per employee of £27.7k, this is less efficient (£48.3k)
- Pharma-wm Consultancy Limited
£48.3k - Industry AVG
Debtor Days
it gets paid by customers after 25 days, this is near the average (22 days)
- Pharma-wm Consultancy Limited
22 days - Industry AVG
Creditor Days
its suppliers are paid after 138 days, this is slower than average (18 days)
- Pharma-wm Consultancy Limited
18 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pharma-wm Consultancy Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Pharma-wm Consultancy Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 100.4%, this is a higher level of debt than the average (26.3%)
100.4% - Pharma-wm Consultancy Limited
26.3% - Industry AVG
PHARMA-WM CONSULTANCY LIMITED financials
Pharma-Wm Consultancy Limited's latest turnover from January 2024 is estimated at £27.7 thousand and the company has net assets of -£131. According to their latest financial statements, Pharma-Wm Consultancy Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | |
|---|---|---|---|---|---|---|---|
| Turnover | |||||||
| Other Income Or Grants | |||||||
| Cost Of Sales | |||||||
| Gross Profit | |||||||
| Admin Expenses | |||||||
| Operating Profit | |||||||
| Interest Payable | |||||||
| Interest Receivable | |||||||
| Pre-Tax Profit | |||||||
| Tax | |||||||
| Profit After Tax | |||||||
| Dividends Paid | |||||||
| Retained Profit | |||||||
| Employee Costs | |||||||
| Number Of Employees | 1 | 1 | 1 | 2 | 2 | 2 | |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | |
|---|---|---|---|---|---|---|---|
| Tangible Assets | 33,900 | 33,900 | 33,900 | ||||
| Intangible Assets | |||||||
| Investments & Other | 33,900 | ||||||
| Debtors (Due After 1 year) | |||||||
| Total Fixed Assets | 33,900 | 33,900 | 33,900 | 33,900 | |||
| Stock & work in progress | |||||||
| Trade Debtors | 1,924 | 308 | 2,592 | 11,498 | 11,524 | ||
| Group Debtors | |||||||
| Misc Debtors | 59 | 59 | |||||
| Cash | 2,394 | 2,394 | 7,202 | 15,121 | |||
| misc current assets | 3 | ||||||
| total current assets | 1,924 | 308 | 2,592 | 2,456 | 2,453 | 18,700 | 26,645 |
| total assets | 35,824 | 34,208 | 36,492 | 36,356 | 2,453 | 18,700 | 26,645 |
| Bank overdraft | |||||||
| Bank loan | |||||||
| Trade Creditors | 8,152 | 4,103 | 5,449 | ||||
| Group/Directors Accounts | 3,258 | 200 | 89 | 2,199 | |||
| other short term finances | |||||||
| hp & lease commitments | |||||||
| other current liabilities | 960 | 1,065 | 9,765 | 11,049 | |||
| total current liabilities | 8,152 | 4,103 | 5,449 | 4,218 | 1,265 | 9,854 | 13,248 |
| loans | 31,000 | ||||||
| hp & lease commitments | |||||||
| Accruals and Deferred Income | 600 | ||||||
| other liabilities | 27,203 | 30,217 | 30,869 | ||||
| provisions | |||||||
| total long term liabilities | 27,803 | 30,217 | 30,869 | 31,000 | |||
| total liabilities | 35,955 | 34,320 | 36,318 | 35,218 | 1,265 | 9,854 | 13,248 |
| net assets | -131 | -112 | 174 | 1,138 | 1,188 | 8,846 | 13,397 |
| total shareholders funds | -131 | -112 | 174 | 1,138 | 1,188 | 8,846 | 13,397 |
| Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Profit | |||||||
| Depreciation | |||||||
| Amortisation | |||||||
| Tax | |||||||
| Stock | |||||||
| Debtors | 1,616 | -2,284 | 2,533 | -11,439 | -26 | 11,524 | |
| Creditors | 4,049 | -1,346 | 5,449 | ||||
| Accruals and Deferred Income | 600 | -960 | -105 | -8,700 | -1,284 | 11,049 | |
| Deferred Taxes & Provisions | |||||||
| Cash flow from operations | |||||||
| Investing Activities | |||||||
| capital expenditure | |||||||
| Change in Investments | -33,900 | 33,900 | |||||
| cash flow from investments | |||||||
| Financing Activities | |||||||
| Bank loans | |||||||
| Group/Directors Accounts | -3,258 | 3,058 | 111 | -2,110 | 2,199 | ||
| Other Short Term Loans | |||||||
| Long term loans | -31,000 | 31,000 | |||||
| Hire Purchase and Lease Commitments | |||||||
| other long term liabilities | -3,014 | -652 | 30,869 | ||||
| share issue | |||||||
| interest | |||||||
| cash flow from financing | |||||||
| cash and cash equivalents | |||||||
| cash | -2,394 | -4,808 | -7,919 | 15,121 | |||
| overdraft | |||||||
| change in cash | -2,394 | -4,808 | -7,919 | 15,121 |
pharma-wm consultancy limited Credit Report and Business Information
Pharma-wm Consultancy Limited Competitor Analysis
Perform a competitor analysis for pharma-wm consultancy limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in WF1 area or any other competitors across 12 key performance metrics.
pharma-wm consultancy limited Ownership
PHARMA-WM CONSULTANCY LIMITED group structure
Pharma-Wm Consultancy Limited has no subsidiary companies.
Ultimate parent company
PHARMA-WM CONSULTANCY LIMITED
10593192
pharma-wm consultancy limited directors
Pharma-Wm Consultancy Limited currently has 2 directors. The longest serving directors include Mr Wasim Malik (Jan 2017) and Mrs Tayyaba Jabeen (Mar 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Wasim Malik | United Kingdom | 41 years | Jan 2017 | - | Director |
| Mrs Tayyaba Jabeen | England | 30 years | Mar 2018 | - | Director |
P&L
January 2024turnover
27.7k
+39%
operating profit
-19
0%
gross margin
22.7%
+4.72%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
January 2024net assets
-131
+0.17%
total assets
35.8k
+0.05%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
pharma-wm consultancy limited company details
company number
10593192
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
January 2017
age
8
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
January 2024
previous names
N/A
accountant
UK TAX ACCOUNTANTS
auditor
-
address
unit 4, the office campus, paragon busin, wakefield, WF1 2UY
Bank
-
Legal Advisor
-
pharma-wm consultancy limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pharma-wm consultancy limited.
pharma-wm consultancy limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMA-WM CONSULTANCY LIMITED. This can take several minutes, an email will notify you when this has completed.
pharma-wm consultancy limited Companies House Filings - See Documents
| date | description | view/download |
|---|
